NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age

References

• Porter KR, McCarthy BJ, Freels S, et al. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol 2010;12(6):520-7
   PubMed Web of Science ®Google Scholar
• Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 2012;14(Suppl 5):v1-49
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-96
   PubMed Web of Science ®Google Scholar
• Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359(5):492-507
   PubMed Web of Science ®Google Scholar
• Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA 2013;310(17):1842-50
   PubMed Web of Science ®Google Scholar
• Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014;370(8):709-22
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014;370(8):699-708
   PubMed Web of Science ®Google Scholar
• Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28(11):1963-72
   PubMed Web of Science ®Google Scholar
• Ng K, Kim R, Kesari S, et al. Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights. J Neurooncol 2012;107(1):1-12
   PubMed Web of Science ®Google Scholar
• Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006;7(5):392-401
   PubMed Web of Science ®Google Scholar
• Westphal M, Lamszus K. The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat Rev Neurosci 2011;12(9):495-508
   PubMed Web of Science ®Google Scholar
• Van Meir EG, Hadjipanayis CG, Norden AD, et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010;60(3):166-93
   PubMed Web of Science ®Google Scholar
• Fisher JL, Schwartzbaum JA, Wrensch M, Wiemels JL. Epidemiology of brain tumors. Neurol Clin 2007;25(4):867-90, vii
   PubMed Web of Science ®Google Scholar
• Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007;356(15):1527-35
   PubMed Web of Science ®Google Scholar
• Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-8
   PubMed Web of Science ®Google Scholar
• Glantz M, Chamberlain M, Liu Q, et al. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 2003;97(9):2262-6
   PubMed Web of Science ®Google Scholar
• Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17(1):98-110
   PubMed Web of Science ®Google Scholar
• Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010;17(5):510-22
   PubMed Web of Science ®Google Scholar
• Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012;483(7390):479-83
   PubMed Web of Science ®Google Scholar
• Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155(2):462-77
   PubMed Web of Science ®Google Scholar
• Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9(3):157-73
   PubMed Web of Science ®Google Scholar
• Carro MS, Lim WK, Alvarez MJ, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010;463(7279):318-25
   PubMed Web of Science ®Google Scholar
• Sottoriva A, Spiteri I, Piccirillo SG, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 2013;110(10):4009-14
   PubMed Web of Science ®Google Scholar
• Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014;344(6190):1396-401
   PubMed Web of Science ®Google Scholar
• Basseres DS, Baldwin AS. NF-κB and IκB kinase pathways in oncogenic initiation and progression. Oncogene 2006;25(51):6817-30
   PubMed Web of Science ®Google Scholar
• Hoffmann A, Baltimore D. Circuitry of NF-κB signaling. Immunol Rev 2006;210:171-86
   PubMed Web of Science ®Google Scholar
• Karin M. NF-κB and cancer: mechanisms and targets. Mol Carcinog 2006;45(6):355-61
   PubMed Web of Science ®Google Scholar
• Perkins ND. The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer 2012;12(2):121-32
   PubMed Web of Science ®Google Scholar
• Bhat KP, Balasubramaniyan V, Vaillant B, et al. Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell 2013;24(3):331-46
   PubMed Web of Science ®Google Scholar
• Karlebach G, Shamir R. Minimally perturbing a gene regulatory network to avoid a disease phenotype: the glioma network as a test case. BMC Syst Biol 2010;4:15
   PubMedGoogle Scholar
• Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 2011;70(Suppl 1):i104-8
   PubMedGoogle Scholar
• Hayashi S, Yamamoto M, Ueno Y, et al. Expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1, and c-Myc in human astrocytomas. Neurol Med Chir (Tokyo) 2001;41(4):187-95
   PubMedGoogle Scholar
• Kargiotis O, Rao JS, Kyritsis AP. Mechanisms of angiogenesis in gliomas. J Neurooncol 2006;78(3):281-93
   PubMed Web of Science ®Google Scholar
• Huang P, Rani MR, Ahluwalia MS, et al. Endothelial expression of TNF receptor-1 generates a proapoptotic signal inhibited by integrin alpha6beta1 in glioblastoma. Cancer Res 2012;72(6):1428-37
   PubMedGoogle Scholar
• Nogueira L, Ruiz-Ontañon P, Vazquez-Barquero A, et al. The NFkappaB pathway: a therapeutic target in glioblastoma. Oncotarget 2011;2(8):646-53
   PubMedGoogle Scholar
• Puliyappadamba VT, Chakraborty S, Chauncey SS, et al. Opposing effect of EGFRWT on EGFRvIII-mediated NF-kappaB activation with RIP1 as a cell death switch. Cell Rep 2013;4(4):764-75
   PubMedGoogle Scholar
• Bonavia R, Inda MM, Vandenberg S, et al. EGFRvIII promotes glioma angiogenesis and growth through the NF-kappaB, interleukin-8 pathway. Oncogene 2012;31(36):4054-66
   PubMedGoogle Scholar
• Yang W, Xia Y, Cao Y, et al. EGFR-induced and PKCepsilon monoubiquitylation-dependent NF-kappaB activation upregulates PKM2 expression and promotes tumorigenesis. Mol Cell 2012;48(5):771-84
   PubMedGoogle Scholar
• Tanaka K, Babic I, Nathanson D, et al. Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance. Cancer Discov 2011;1(6):524-38
   PubMed Web of Science ®Google Scholar
• Atkinson GP, Nozell SE, Benveniste ET. NF-kappaB and STAT3 signaling in glioma: targets for future therapies. Expert Rev Neurother 2010;10(4):575-86
   PubMed Web of Science ®Google Scholar
• Holmes KM, Annala M, Chua CY, et al. Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-kappaB network. Proc Natl Acad Sci USA 2012;109(9):3475-80
   PubMedGoogle Scholar
• Nozell S, Laver T, Moseley D, et al. The ING4 tumor suppressor attenuates NF-kappaB activity at the promoters of target genes. Mol Cell Biol 2008;28(21):6632-45
   PubMedGoogle Scholar
• Atkinson GP, Nozell SE, Harrison DK, et al. The prolyl isomerase Pin1 regulates the NF-kappaB signaling pathway and interleukin-8 expression in glioblastoma. Oncogene 2009;28(42):3735-45
   PubMed Web of Science ®Google Scholar
• Zhang T, Park KA, Li Y, et al. PHF20 regulates NF-kappaB signalling by disrupting recruitment of PP2A to p65. Nat Commun 2013;4:2062
   PubMedGoogle Scholar
• Bredel M, Scholtens DM, Yadav AK, et al. NFKBIA deletion in glioblastomas. N Engl J Med 2011;364(7):627-37
   PubMed Web of Science ®Google Scholar
• Patane M, Porrati P, Bottega E, et al. Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres. Mol Cancer 2013;12:160
   PubMedGoogle Scholar
• Nogueira L, Ruiz-Ontañon P, Vazquez-Barquero A, et al. Blockade of the NFkappaB pathway drives differentiating glioblastoma-initiating cells into senescence both in vitro and in vivo. Oncogene 2011;30(32):3537-48
   PubMedGoogle Scholar
• Hjelmeland AB, Wu Q, Wickman S, et al. Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biol 2010;8(2):e1000319
   PubMed Web of Science ®Google Scholar
• Hummel R, Maurer J, Haier J. MicroRNAs in brain tumors : a new diagnostic and therapeutic perspective? Mol Neurobiol 2011;44(3):223-34
   PubMedGoogle Scholar
• Ciafre SA, Galardi S, Mangiola A, et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 2005;334(4):1351-8
   PubMed Web of Science ®Google Scholar
• Papagiannakopoulos T, Shapiro A, Kosik KS. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 2008;68(19):8164-72
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu W, Chao T, et al. MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. Cancer Lett 2008;272(2):197-205
   PubMedGoogle Scholar
• Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005;65(14):6029-33
   PubMed Web of Science ®Google Scholar
• Lakomy R, Sana J, Hankeova S, et al. MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Sci 2011;102(12):2186-90
   PubMed Web of Science ®Google Scholar
• Li Y, Li W, Yang Y, et al. MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res 2009;1286:13-18
   PubMed Web of Science ®Google Scholar
• Song L, Liu L, Wu Z, et al. TGF-beta induces miR-182 to sustain NF-kappaB activation in glioma subsets. J Clin Invest 2012;122(10):3563-78
   PubMedGoogle Scholar
• Jiang L, Lin C, Song L, et al. MicroRNA-30e* promotes human glioma cell invasiveness in an orthotopic xenotransplantation model by disrupting the NF-kappaB/IkappaBalpha negative feedback loop. J Clin Invest 2012;122(1):33-47
   PubMed Web of Science ®Google Scholar
• Wang S, Jiao B, Geng S, et al. Concomitant microRNA-31 downregulation and radixin upregulation predicts advanced tumor progression and unfavorable prognosis in patients with gliomas. J Neurol Sci 2014;338(1-2):71-6
   PubMedGoogle Scholar
• Hua D, Ding D, Han X, et al. Human miR-31 targets radixin and inhibits migration and invasion of glioma cells. Oncol Rep 2012;27(3):700-6
   PubMed Web of Science ®Google Scholar
• Srinivasan S, Patric IR, Somasundaram K. A ten-microRNA expression signature predicts survival in glioblastoma. PLoS One 2011;6(3):e17438
   PubMed Web of Science ®Google Scholar
• Yang G, Han D, Chen X, et al. MiR-196a exerts its oncogenic effect in glioblastoma multiforme by inhibition of IkappaBalpha both in vitro and in vivo. Neuro Oncol 2014;16(5):652-61
   PubMed Web of Science ®Google Scholar
• Song L, Lin C, Gong H, et al. miR-486 sustains NF-kappaB activity by disrupting multiple NF-kappaB-negative feedback loops. Cell Res 2013;23(2):274-89
   PubMed Web of Science ®Google Scholar
• Xia H, Yan Y, Hu M, et al. MiR-218 sensitizes glioma cells to apoptosis and inhibits tumorigenicity by regulating ECOP-mediated suppression of NF-kappaB activity. Neuro Oncol 2013;15(4):413-22
   PubMedGoogle Scholar
• Yin D, Zhou H, Kumagai T, et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 2005;24(3):344-54
   PubMed Web of Science ®Google Scholar
• Phuphanich S, Supko JG, Carson KA, et al. Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J Neurooncol 2010;100(1):95-103
   PubMed Web of Science ®Google Scholar
• Coupienne I, Bontems S, Dewaele M, et al. NF-kappaB inhibition improves the sensitivity of human glioblastoma cells to 5-aminolevulinic acid-based photodynamic therapy. Biochem Pharmacol 2011;81(5):606-16
   PubMedGoogle Scholar
• Shukla S, Pia Patric IR, Thinagararjan S, et al. A DNA methylation prognostic signature of glioblastoma: identification of NPTX2-PTEN-NF-kappaB nexus. Cancer Res 2013;73(22):6563-73
   PubMed Web of Science ®Google Scholar
• Fukushima T, Kawaguchi M, Yorita K, et al. Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-kappaB, on glioblastoma. Neuro Oncol 2012;14(1):19-28
   PubMed Web of Science ®Google Scholar
• Brassesco MS, Roberto GM, Morales AG, et al. Inhibition of NF- kappa B by Dehydroxymethylepoxyquinomicin suppresses invasion and synergistically potentiates temozolomide and gamma -radiation cytotoxicity in glioblastoma cells. Chemother Res Pract 2013;2013:593020
   PubMedGoogle Scholar
• McFarland BC, Hong SW, Rajbhandari R, et al. NF-kappaB-induced IL-6 ensures STAT3 activation and tumor aggressiveness in glioblastoma. PLoS One 2013;8(11):e78728
   Google Scholar
• Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01793935&Search=Search
   Google Scholar
• Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity 2012;36(4):503-14
   PubMed Web of Science ®Google Scholar
• Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009;9(11):798-809
   PubMed Web of Science ®Google Scholar
• Wagner KU, Schmidt JW. The two faces of Janus kinases and their respective STATs in mammary gland development and cancer. J Carcinog 2011;10:32
   PubMedGoogle Scholar
• Decker T, Kovarik P. Serine phosphorylation of STATs. Oncogene 2000;19(21):2628-37
   PubMed Web of Science ®Google Scholar
• Aziz MH, Hafeez BB, Sand JM, et al. Protein kinase Cvarepsilon mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression, and cell invasion in various human cancer cell lines through integration with MAPK cascade (RAF-1, MEK1/2, and ERK1/2). Oncogene 2010;29(21):3100-9
   PubMedGoogle Scholar
• Xu Y, Li Z, Zhang C, et al. Knockdown of PKCepsilon expression inhibits growth, induces apoptosis and decreases invasiveness of human glioma cells partially through Stat3. J Mol Neurosci 2014. [Epub ahead of print]
   Google Scholar
• Kim E, Kim M, Woo DH, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 2013;23(6):839-52
   PubMed Web of Science ®Google Scholar
• Brantley EC, Nabors LB, Gillespie GY, et al. Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. Clin Cancer Res 2008;14(15):4694-704
   PubMedGoogle Scholar
• Lee K, Byun K, Hong W, et al. Proteome-wide discovery of mislocated proteins in cancer. Genome Res 2013;23(8):1283-94
   PubMedGoogle Scholar
• Brantley EC, Benveniste EN. Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res 2008;6(5):675-84
   PubMed Web of Science ®Google Scholar
• Lin GS, Yang LJ, Wang XF, et al. STAT3 Tyr705 phosphorylation affects clinical outcome in patients with newly diagnosed supratentorial glioblastoma. Med Oncol 2014;31(4):924
   PubMedGoogle Scholar
• Halliday J, Helmy K, Pattwell SS, et al. In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift. Proc Natl Acad Sci USA 2014;111(14):5248-53
   PubMedGoogle Scholar
• Kim TM, Huang W, Park R, et al. A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. Cancer Res 2011;71(9):3387-99
   PubMed Web of Science ®Google Scholar
• Cui X, Liu J, Bai L, et al. Interleukin-6 induces malignant transformation of rat mesenchymal stem cells in association with enhanced signaling of signal transducer and activator of transcription 3. Cancer Sci 2014;105(1):64-71
   PubMedGoogle Scholar
• Wang H, Lathia JD, Wu Q, et al. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 2009;27(10):2393-404
   PubMed Web of Science ®Google Scholar
• Cao Y, Lathia JD, Eyler CE, et al. Erythropoietin receptor signaling through STAT3 is required for glioma stem cell maintenance. Genes Cancer 2010;1(1):50-61
   PubMedGoogle Scholar
• Doucette TA, Kong LY, Yang Y, et al. Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol 2012;14(9):1136-45
   PubMed Web of Science ®Google Scholar
• Kim Y, Kim E, Wu Q, et al. Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. Genes Dev 2012;26(11):1247-62
   PubMed Web of Science ®Google Scholar
• Fan QW, Cheng CK, Gustafson WC, et al. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell 2013;24(4):438-49
   PubMed Web of Science ®Google Scholar
• Garnett J, Chumbalkar V, Vaillant B, et al. Regulation of HGF expression by DeltaEGFR-mediated c-Met activation in glioblastoma cells. Neoplasia 2013;15(1):73-84
   PubMedGoogle Scholar
• Zhou M, Wang H, Zhou K, et al. A novel EGFR isoform confers increased invasiveness to cancer cells. Cancer Res 2013;73(23):7056-67
   PubMedGoogle Scholar
• Frattini V, Trifonov V, Chan JM, et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 2013;45(10):1141-9
   PubMed Web of Science ®Google Scholar
• Wei J, Wang F, Kong LY, et al. miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res 2013;73(13):3913-26
   PubMed Web of Science ®Google Scholar
• Sumazin P, Yang X, Chiu HS, et al. An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell 2011;147(2):370-81
   PubMed Web of Science ®Google Scholar
• Veeriah S, Brennan C, Meng S, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci USA 2009;106(23):9435-40
   PubMedGoogle Scholar
• Ortiz B, Fabius AW, Wu WH, et al. Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis. Proc Natl Acad Sci USA 2014;111(22):8149-54
   PubMedGoogle Scholar
• Nilsson CL, Dillon R, Devakumar A, et al. Quantitative phosphoproteomic analysis of the STAT3/IL-6/HIF1alpha signaling network: an initial study in GSC11 glioblastoma stem cells. J Proteome Res 2010;9(1):430-43
   PubMed Web of Science ®Google Scholar
• da Fonseca AC, Badie B. Microglia and macrophages in malignant gliomas: recent discoveries and implications for promising therapies. Clin Dev Immunol 2013;2013:264124
   PubMedGoogle Scholar
• Wu A, Wei J, Kong LY, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol 2010;12(11):1113-25
   PubMed Web of Science ®Google Scholar
• Wei J, Barr J, Kong LY, et al. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther 2010;9(1):67-78
   PubMed Web of Science ®Google Scholar
• Wei J, Wu A, Kong LY, et al. Hypoxia potentiates glioma-mediated immunosuppression. PLoS One 2011;6(1):e16195
   PubMed Web of Science ®Google Scholar
• McFarland BC, Ma JY, Langford CP, et al. Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther 2011;10(12):2384-93
   PubMed Web of Science ®Google Scholar
• Zheng Q, Han L, Dong Y, et al. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma. Neuro Oncol 2014;16(9):1229-43
   PubMedGoogle Scholar
• He K, Qi Q, Chan CB, et al. Blockade of glioma proliferation through allosteric inhibition of JAK2. Sci Signal 2013;6(283):ra55
   PubMedGoogle Scholar
• Ball S, Li C, Li PK, Lin J. The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells. PLoS One 2011;6(4):e18820
   PubMed Web of Science ®Google Scholar
• Kohsaka S, Wang L, Yachi K, et al. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Mol Cancer Ther 2012;11(6):1289-99
   PubMed Web of Science ®Google Scholar
• de Groot J, Liang J, Kong LY, et al. Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma. Oncotarget 2012;3(9):1036-48
   PubMed Web of Science ®Google Scholar
• Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15(3):220-31
   PubMed Web of Science ®Google Scholar
• Lu KV, Chang JP, Parachoniak CA, et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012;22(1):21-35
   PubMed Web of Science ®Google Scholar
• Lu KV, Bergers G. Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. CNS Oncol 2013;2(1):49-65
   PubMedGoogle Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140(6):883-99
   PubMed Web of Science ®Google Scholar
• Fan Y, Mao R, Yang J. NF-kappaB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell 2013;4(3):176-85
   PubMed Web of Science ®Google Scholar
• Kesanakurti D, Chetty C, Rajasekhar Maddirela D, et al. Essential role of cooperative NF-kappaB and Stat3 recruitment to ICAM-1 intronic consensus elements in the regulation of radiation-induced invasion and migration in glioma. Oncogene 2013;32(43):5144-55
   PubMedGoogle Scholar
• Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009;139(4):693-706
   PubMed Web of Science ®Google Scholar
• Iliopoulos D, Jaeger SA, Hirsch HA, et al. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010;39(4):493-506
   PubMed Web of Science ®Google Scholar
• Lee H, Herrmann A, Deng JH, et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009;15(4):283-93
   PubMed Web of Science ®Google Scholar
• Xiang M, Birkbak NJ, Vafaizadeh V, et al. STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-kappaB to IL-6 signaling axis and STAT3-driven cancer phenotypes. Sci Signal 2014;7(310):ra11
   PubMed Web of Science ®Google Scholar
• Rokavec M, Wu W, Luo JL. IL 6-mediated suppression of miR-200c directs constitutive activation of inflammatory signaling circuit driving transformation and tumorigenesis. Mol Cell 2012;45(6):777-89
   PubMed Web of Science ®Google Scholar
• Dominguez I, Sonenshein GE, Seldin DC. Protein kinase CK2 in health and disease: CK2 and its role in Wnt and NF-kappaB signaling: linking development and cancer. Cell Mol Life Sci 2009;66(11-12):1850-7
   PubMed Web of Science ®Google Scholar
• Zheng Y, Qin H, Frank SJ, et al. A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway. Blood 2011;118(1):156-66
   PubMed Web of Science ®Google Scholar
• Zheng Y, McFarland BC, Drygin D, et al. Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma. Clin Cancer Res 2013;19(23):6484-94
   PubMed Web of Science ®Google Scholar
• Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00621686&Search=Search
   Google Scholar
• Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00720356&Search=Search
   Google Scholar
• Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00892177&Search=Search
   Google Scholar
• Iwamaru A, Szymanski S, Iwado E, et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2007;26(17):2435-44
   PubMed Web of Science ®Google Scholar
• Hussain SF, Kong LY, Jordan J, et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 2007;67(20):9630-6
   PubMed Web of Science ®Google Scholar
• Kong LY, Wu AS, Doucette T, et al. Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses. Clin Cancer Res 2010;16(23):5722-33
   PubMed Web of Science ®Google Scholar
• Weissenberger J, Priester M, Bernreuther C, et al. Dietary curcumin attenuates glioma growth in a syngeneic mouse model by inhibition of the JAK1,2/STAT3 signaling pathway. Clin Cancer Res 2010;16(23):5781-95
   PubMedGoogle Scholar
• Senft C, Polacin M, Priester M, et al. The nontoxic natural compound Curcumin exerts anti-proliferative, anti-migratory, and anti-invasive properties against malignant gliomas. BMC Cancer 2010;10:491
   PubMed Web of Science ®Google Scholar
• Juttler E, Potrovita I, Tarabin V, et al. The cannabinoid dexanabinol is an inhibitor of the nuclear factor-kappa B (NF-kappa B). Neuropharmacology 2004;47(4):580-92
   PubMed Web of Science ®Google Scholar
• Kumar AP, Garcia GE, Orsborn J, et al. 2-Methoxyestradiol interferes with NF kappa B transcriptional activity in primitive neuroectodermal brain tumors: implications for management. Carcinogenesis 2003;24(2):209-16
   PubMed Web of Science ®Google Scholar
• Muh CR, Joshi S, Singh AR, et al. PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1alpha suppression. J Neurooncol 2014;116(1):89-97
   PubMedGoogle Scholar
• Jackson CM, Lim M, Drake CG. Immunotherapy for brain cancer: recent progress and future promise. Clin Cancer Res 2014;20(14):3651-9
   PubMed Web of Science ®Google Scholar
• A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01498328+&Search=Search
   Google Scholar
• Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01814813&Search=Search
   Google Scholar
• Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma. Available from: www.clinicaltrials.gov/ct2/results?term=NCT02010606&Search=Search
   Google Scholar
• Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01522820&Search=Search
   Google Scholar
• Leder K, Pitter K, Laplant Q, et al. Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules. Cell 2014;156(3):603-16
   PubMed Web of Science ®Google Scholar
• A Phase I Trial of WP1066. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01904123&Search=Search
   Google Scholar
• Curcumin Bioavailability in Glioblastoma Patients. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01712542&Search=Search
   Google Scholar
• Dexanabinol in Patients With Brain Cancer. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01654497&Search=Search
   Google Scholar
• Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00306618&Search=Search
   Google Scholar
• Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM). Available from: www.clinicaltrials.gov/ct2/results?term=NCT00481455&Search=Search
   Google Scholar
• Bortezomib in Treating Patients With Recurrent Glioma. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00006773&Search=Search
   Google Scholar
• Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00544284&Search=Search
   Google Scholar
• Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01435395&Search=Search
   Google Scholar
• Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00998010&Search=Search
   Google Scholar
• Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00611325&Search=Search
   Google Scholar
• Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00108069&Search=Search
   Google Scholar
• Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00641706&Search=Search
   Google Scholar